Tag: Gilead Sciences
Gilead Agrees to Collaborate on the Strata Precision Indications for Approved...
Gilead Sciences and Strata Oncology have signed an agreement in which Gilead has agreed to collaborate on the Strata Precision Indications for Approved THerapies (Strata PATH™; NCT05097599) study by providing sacituzumab govitecan-hziy (Trodelvy®) for eligible patients with cancer.
What to Expect at ESMO 2022: Sacituzumab Govitecan Show PFS Benefits...
New data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating sacituzumab govitecan-hziy* (Trodelvy®, Gilead Sciences) versus comparator chemotherapies (physicians’...
Sacituzumab Govitecan Approved in China for Second-Line Metastatic Triple-Negative Breast Cancer
China's National Medical Products Administration (NMPA) has approved sacituzumab govitecan (Trodelvy®; Gilead Sciences) for the treatment of adult patients with unresectable locally advanced or metastatic...
Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...
Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...
Gilead Finalizes Acquisition of Immunomedics
Earlier today Foster City, California-based Gilead Sciences confirmed that it had completed the previously announced transaction to acquire Immunomedics for approximately U.S. $ 21...
